References
- Watts NB, Diab DL: Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95: 1555–1565, 2010
- Schilcher J, Michaëlsson K, Aspenberg P: Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364: 1728–1737, 2011
- Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al: American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267–2294, 2010
- Kwek EB, Goh SK, Koh JS, Png MA, Howe TS: An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39: 224–231, 2008
- Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG: Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346–350, 2008
- Chan SS, Rosenberg ZS, Chan K, Capeci C: Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: Imaging features. AJR Am J Roentgenol 194: 1581–1586, 2010
- Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS: Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89: 349–353, 2007
- Sellmeyer DE: Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 304: 1480–1484, 2010
- Fleisch H, Reszka A, Rodan G, Rogers M: Bisphosphonates: Mechanisms of Action. Principles of Bone Biology. Edited by JP Bilezikian, LG Raisz, GA Rodan, 2nd ed. Academic Press, San Diego, 2002, pp. 1361–1385
- Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, et al: Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199, 2004
- Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, et al: Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362: 1761–1771, 2010
- Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, et al: Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41: 378–385, 2007
- Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294–1301, 2005
- Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93: 2948–2952, 2008
- Capeci CM, Tejwani NC: Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91: 2556–2561, 2009
- Paparodis R, Buehring B, Pelley E, Binkley N: A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 21: 1–17, 2013